Modern treatment methods have led to major improvements in the survival rate of children with Wilms' tumor (WT). Combined therapy using surgery, radiation therapy and chemotherapy now cures 90% of patients with favorable histology WT. Those with renal tumors of unfavorable histology, especially those with metastases, either synchronous or metachronous, are at higher risk. Their survival is in the 50-65% range, and better treatments clearly are needed. At the same time, all therapies have their associated risks and complications, and some are costly and burdensome for the medical staff and the family. Refinements of therapy for children with a good outlook are therefore needed to increase efficiency, and reduce risks and costs. NWTS-4 is designed to achieve these objectives through better understanding of the renal tumors of childhood, their epidemiology and the late effects of successful therapy, while conducting clinical trials of novel therapies. These trials address the following question: Can single daily doses of effective chemotherapeutic agents given more frequently over a shorter interval improve the outlook while decreasing costs and family stress? The NWTS thus has undertaken a new task: the reduction of the socioeconomic burdens of therapy while continuing to strive for more cures and continuing its pioneering studies of the delayed consequences of Wilms' tumor treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA042326-06
Application #
3558422
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1985-09-01
Project End
1991-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Perlman, Elizabeth J; Gadd, Samantha; Arold, Stefan T et al. (2015) MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun 6:10013
Walz, Amy L; Ooms, Ariadne; Gadd, Samantha et al. (2015) Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286-97
Gooskens, Saskia L; Gadd, Samantha; Guidry Auvil, Jaime M et al. (2015) TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. Oncotarget 6:15828-41
Maschietto, Mariana; Williams, Richard D; Chagtai, Tasnim et al. (2014) TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One 9:e109924
Green, Daniel M; Breslow, Norman E; D'Angio, Giulio J et al. (2014) Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 61:134-9
Malogolowkin, M; Spreafico, F; Dome, J S et al. (2013) Incidence and outcomes of patients with late recurrence of Wilms' tumor. Pediatr Blood Cancer 60:1612-5
Gow, Kenneth W; Barnhart, Douglas C; Hamilton, Thomas E et al. (2013) Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee. J Pediatr Surg 48:34-8
Kalapurakal, John A; Perlman, Elizabeth J; Seibel, Nita L et al. (2013) Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5. Int J Radiat Oncol Biol Phys 85:428-31
Kieran, Kathleen; Anderson, James R; Dome, Jeffrey S et al. (2013) Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Children's Oncology Group. J Pediatr Surg 48:1598-603
Green, Daniel M; Lange, Jane M; Qu, Annie et al. (2013) Pulmonary disease after treatment for Wilms tumor: a report from the national wilms tumor long-term follow-up study. Pediatr Blood Cancer 60:1721-6

Showing the most recent 10 out of 140 publications